• Advertise
  • Membership
  • Sign inSUBSCRIBE
Legal Era
X
Sign in
  • Home
  • News
    +
    • From the Courts
    • Policy & Law
    • Supreme Court (India)
    • High Court (India)
    • TAX Updates
    • MARKET WATCH
    • Deal Street
    • Global Insights
    • IBC Cases
    • Hires & Moves
    • IP News
    • Competition Verdict
    • Global Articles
    • Global Deals
  • Articles
    +
    • ABOUT THE LAW
    • AWARDS & ACCOLADES
    • Aerospace
    • Agriculture
    • Alternate Dispute Resolution
    • Banking and Finance
    • Bankruptcy
    • Book Review
    • Bribery & Corruption
    • Commercial Litigation
    • Competition Law
    • Conference Reports
    • Consumer Products
    • Contract
    • Corporate Governance
    • Corporate Law
    • Covid-19
    • Cryptocurrency
    • Cybersecurity
    • Data Protection
    • Defence
    • Digital Economy
    • E-commerce
    • Employment Law
    • Energy and Natural Resources
    • Entertainment and Sports Law
    • Environmental Law
    • FDI
    • Food and Beverage
    • Health Care
    • IBC Diaries
    • Insurance Law
    • Intellectual Property
    • International Law
    • Labour Laws
    • Litigation
    • Litigation Funding
    • Manufacturing
    • Mergers & Acquisitions
    • NFTs
    • Privacy
    • Private Equity
    • Project Finance
    • Real Estate
    • Risk and Compliance
    • Technology Media and Telecom
    • Tributes
    • Zoom In
    • Take On Board
    • In Focus
    • Law & Policy and Regulation
    • IP & Tech Era
    • Viewpoint
    • Arbitration & Mediation
    • Tax
    • Student Corner
    • ESG
    • Gaming
    • Inclusion & Diversity
  • Law Firms
    +
    • Global Law Firm
    • Asia Law Firm
    • India Law Firm
  • In-House
  • Rankings
  • E-Magazine
  • Legal Era TV
  • Events
  • News
    • From the Courts
    • Policy & Law
    • Supreme Court (India)
    • High Court (India)
    • TAX Updates
    • MARKET WATCH
    • Deal Street
    • Global Insights
    • IBC Cases
    • Hires & Moves
    • IP News
    • Competition Verdict
    • Global Articles
    • Global Deals
  • Articles
    • ABOUT THE LAW
    • AWARDS & ACCOLADES
    • Aerospace
    • Agriculture
    • Alternate Dispute Resolution
    • Banking and Finance
    • Bankruptcy
    • Book Review
    • Bribery & Corruption
    • Commercial Litigation
    • Competition Law
    • Conference Reports
    • Consumer Products
    • Contract
    • Corporate Governance
    • Corporate Law
    • Covid-19
    • Cryptocurrency
    • Cybersecurity
    • Data Protection
    • Defence
    • Digital Economy
    • E-commerce
    • Employment Law
    • Energy and Natural Resources
    • Entertainment and Sports Law
    • Environmental Law
    • FDI
    • Food and Beverage
    • Health Care
    • IBC Diaries
    • Insurance Law
    • Intellectual Property
    • International Law
    • Labour Laws
    • Litigation
    • Litigation Funding
    • Manufacturing
    • Mergers & Acquisitions
    • NFTs
    • Privacy
    • Private Equity
    • Project Finance
    • Real Estate
    • Risk and Compliance
    • Technology Media and Telecom
    • Tributes
    • Zoom In
    • Take On Board
    • In Focus
    • Law & Policy and Regulation
    • IP & Tech Era
    • Viewpoint
    • Arbitration & Mediation
    • Tax
    • Student Corner
    • ESG
    • Gaming
    • Inclusion & Diversity
  • Law Firms
    • Global Law Firm
    • Asia Law Firm
    • India Law Firm
  • In-House
  • Rankings
  • E-Magazine
  • Legal Era TV
  • Events

Top Stories

  • Freshfields
    Finance partner Carol Van der Vorst
  • Time
    Time limit of 45 days under SARFAESI is
  • Justices-Uday-Umesh-Lalit-&-Aniruddha-Bose-&-Sudhanshu-Dhulia
    Supreme Court reserves judgement on
  • Justice-Yashwant-Varma
    Delhi High Court rules on not ousting
  • Deborah-Enix-Ross
    Deborah Enix-Ross sworn in as president
  • Dentons
    Dentons assists IMC Industrial Group in
  • Bombay-High-Court
    Bombay High Court rejects recovery
  • Pallavi-Bedi
    Erstwhile Partner at Luthra and Luthra -
  • WhatsApp
    NCLAT rules in favour of WhatsAPP, says
  • Jaewoo-Lee
    Jaewoo Lee appointed as the Managing
HomeNewsGlobal Insights
6 July 2022 3:30 AM GMT

CureVac obtains patent lawsuit against BioNTech

By: Susmita Ghosh
CureVac obtains patent lawsuit against BioNTech

CureVac obtains patent lawsuit against BioNTech • CureVac requests "appropriate recompense" for its mRNA innovation • Will not attempt to halt the sale and distribution of COVID vaccines. • BioNTech asserts its work is unique and will support it Amid the intense race to create a coronavirus vaccine, CureVac (5CV.DE) has launched a patent action in Germany suing BioNTech (22UAy.DE)...

ToRead the Full Story, Subscribe to Legal Era

Access the exclusive LEGAL ERAStories,Editorial and Expert Opinion

Subscribe Now
AlreadyaSubscriber?SigninNow
View Plans


CureVac obtains patent lawsuit against BioNTech

• CureVac requests "appropriate recompense" for its mRNA innovation

• Will not attempt to halt the sale and distribution of COVID vaccines.

• BioNTech asserts its work is unique and will support it

Amid the intense race to create a coronavirus vaccine, CureVac (5CV.DE) has launched a patent action in Germany suing BioNTech (22UAy.DE) over the latter's use of mRNA technology. This is one of the first instances of a firm going to court that is known to have occurred.

The German-based biotech firm says that BioNTech and its two subsidiaries violated its proprietary information and demands "appropriate recompense" from them.

Chief Executive Franz-Werner Haas did not rule out further legal proceedings against BioNTech collaborator Pfizer (PFE.N) or mRNA vaccine producer Moderna when questioned during a media teleconference (MRNA.O).

BioNTech claimed that its work was unique. In a statement, BioNTech stated, "We will firmly protect it against all charges of patent infringement."

mRNA technology has been the subject of more than 20 years of research at CureVac, some of which was utilized by BioNTech and Pfizer in the creation and marketing of their Comirnaty coronavirus vaccine.

According to Haas, "several years of study have also contributed to the effectiveness of the mRNA vaccines and made that achievable." "From our perspective, respecting the associated ownership rights is self-evident."

Utilizing mRNA technology, vaccines and medications direct human cells to make beneficial proteins. MRNA, long regarded as a mysterious technology with hazy future prospects, saw usage for the first time when it was included into vaccinations during the pandemic.

CureVac, which reported a 2021 loss of 412 million euros ($423 million), did not find Haas' offer to be a suitable reward.

With the pandemic fading, BioNTech anticipates vaccine sales of up to 17 billion euros ($17.5 billion) in 2022, down from 19 billion euros in 2021.

According to CureVac, no legal action would be taken, nor was an injunction sought to prevent the manufacture, sale, or distribution of the vaccine.

When the epidemic was at its worst, CureVac would not have thought to bring up patent infringement; but, now that the situation has improved, CureVac felt the time was right to do so, as stated by Haas.

Following the news, shares of BioNTech dropped as much as 4.9percent before recovering and trading 2percent t higher at 1354 GMT. CureVac, a German company, had its shares trade 1percent higher after earlier rising as much as 4.8 percent.

CureVac's complaint was filed in the Duesseldorf court, which declined to comment.

To establish CureVac's fair contribution in product promotion and marketing in Germany and how it would be properly valued, Haas was circumspect about the possibility of further legal action.

When asked if he would rule out suing Moderna, he responded: "Nothing is being ruled out. We are seriously examining it."

More than 6.3 million people have died due to COVID-19 pandemic, which started in China. This has sparked a race among pharmaceutical companies to be the one to create a vaccine, with BioNTech and Pfizer eventually taking the lead in the Western world.

Following 2021's unsuccessful attempts to commercialise a COVID-19 vaccine, CureVac increased its collaboration with partner GSK (GSK.L) to develop superior vaccines.

In April, 2022 CureVac and GSK announced that pre-clinical mouse trials had demonstrated the high efficacy of their second-generation vaccine candidate, which targets two recent COVID-19 mutations.

Susmita Ghosh

Susmita Ghosh

TAGS:
  • BioNTech 
  • CureVac 
  • mRNA 
  • Franz-Werner Haas 
Next Story
Similar Posts
See More
TAGS:
  • BioNTech 
  • CureVac 
  • mRNA 
  • Franz-Werner Haas 
Trending Now
Can A Retailer Charge More Than MRP?

Can A Retailer Charge More Than MRP?

The Hierarchy of Indian Courts

The Hierarchy of Indian Courts

Freshfields

Finance partner Carol Van der Vorst joins Freshfields

Can an Arbitral Award Be Stayed Upon Surety and Personal Undertaking

Can an Arbitral Award Be Stayed Upon Surety and Personal

Recommended Articles
Can an Arbitral Award Be Stayed Upon Surety and Personal Undertaking

Can an Arbitral Award Be Stayed Upon Surety and Personal

Stamping Out Illegal Streaming Technology – Recent Amendments to The Copyright Act

Stamping Out Illegal Streaming Technology – Recent

The Quincecare Duty of Care Story Continues

The Quincecare Duty of Care Story Continues

Recent Developments and Trends in Diversity & Inclusion in Japan

Recent Developments and Trends in Diversity & Inclusion in

  • News
  • From the Courts
  • Supreme Court (India)
  • High Court (India)
  • Global Insights
  • Deal Street
  • Hires & Moves
  • Refund & Cancellation Policy
  • Articles
  • Zoom In
  • Take On Board
  • In Focus
  • Law & Policy
  • IP & Tech Era
  • Viewpoint
  • Arbitration & Mediation
  • Tax
  • Student Corner
  • Interviews
  • Law Firms
  • E-Magazine
  • Legal Era TV
  • Membership
  • Reader's Feedback
  • Cartoons
  • Subscribe
Follow Us
Subscribe Newsletter
  • 2022© All rights reserved Legal Era Media Group
  • Who We Are
  • Careers
  • Advertise with Us
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
Powered by  Hocalwire
X
X